An Introduction to Blueberry Therapeutics Company Overview - PowerPoint PPT Presentation

David Cook Chief Scientific Officer An Introduction to Blueberry Therapeutics

Company Overview • Founded November 2011 through private investment and grant funding • An experienced, entrepreneurial core team with over 60 years experience in large and small pharma and Biotech • Operates semi-virtually with a range of trusted experts and contract partners • Exploiting a safe, easy to use nanotechnology drug delivery platform to develop new medicines in a range of disease indications • Infection and inflammation • Small and large molecule approaches • Initial focus on the exploitation of a safe nanopolymer based drug delivery platform in over the counter (OTC) medicines • Look for opportunities to collaborate with academic partners to drive forward our R&D projects and exploit our underlying technology platform • Intellectual Property: 5 patents and 6 exclusive licenses to patented technology Blueberry Therapeutics Modern Drug Discovery and Development

Current Portfolio 2015 Preclinical Launch Clinical CTA/IND Risk Profile Tinea pedis L Rapid to market Small Molecule BB2603 Over the counter Onychomycosis M Small molecule BB0305 Acne Medicine L Topical Biologic BB2312 MARKET Acute Wounds Device L BB1601 Atopic Dermatitis H Peptide therapeutic Prescription BB2702 IBD Peptide therapeutic H BB0109 AMR Peptide H BB5000 therapeutics Exploiting our differentiating nanopolymer delivery platform in a range of over the counter healthcare products to marketing authorisation to rapidly generate revenue, benefit our shareholders and invest in long term projects Blueberry Therapeutics Modern Drug Discovery and Development

Drug delivery platform Nanocin ™ : A safe nanopolymer-based drug delivery system • A non-lipid polymer with with over 30 years safe clinical use in human health • Nanocin™ rapidly assembles into nanoparticles – packaging the cargo drug for enhanced delivery Blueberry is exploiting the unique properties of Nanocin ™ to develop a range of topical treatments for infectious and inflammatory disease Blueberry Therapeutics Modern Drug Discovery and Development

Tackling Bacterial Antibiotic Resistance Preclinical proof-of-concept studies 300� - - + - + + - + + - + + - + Nanocin� - - - + + - + + - + + - + + Aptamer� 250� • A new approaches to the treatment of multidrug resistant infection ug/ml� 200� • A platform approach based on nanotech formulated [Oxacillin]� peptide aptamers which target directly the mechanisms 150� of bacterial resistance restoring sensitivity to standard MIC� antibiotics- RESISTANCE BREAKERS 100� • Used in combination with standard antibiotic treatments – Treat MRSA with penicillin! 50� – Potential for a long-term sustained response to 0� AMR MSSA� MRSA� Control� Aptamer� 1� Aptamer� 2� Control� � Scaffold� 2� Scaffold� 1� Restoration of antibiotic sensitivity in clinical isolates of MRSA by protein aptamers blocking the resistance mechanism Blueberry Therapeutics Modern Drug Discovery and Development

Blueberry collaborators Manchester University Leeds Newcastle University University Public Health Liverpool England University Blueberry Therapeutics RVC UCL Sheffield Pharma University SME We are always keen to develop collaborations to help us drive forward our research and exploit this exciting new nanotechnoloy Blueberry Therapeutics Modern Drug Discovery and Development

Thank you Contact: David Cook david.cook@blueberrytherapeutics.com